IP Library Granted Patent US 9,375,315
Granted Patent B2
US 9,375,315 · App. 13/383,293 · Granted Jun 28, 2016

Joint device and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,375,315
App. No.
13/383,293
Filed
Jan 10, 2012
Granted
Jun 28, 2016
Kind
B2
Art Unit
1743
USPC
425/2
Abstract

A mold adapted to be introduced into a joint of a human patient for resurfacing at least one carrying contacting surface of said joint is provided. The mold is adapted to receive material for resurfacing at least one carrying contacting surface of said joint. The mold is further adapted to be resorbed by the human body or melt after having served its purpose. Further, a method of treating hip joint osteoarthritis in a human patient by providing an artificial hip joint surface using a mold is provided. The method comprises the steps of: said mold being placed inside of said hip joint, said mold being injected with a fluid adapted to harden, said fluid hardening inside of said hip joint, said mold being resorbed by the human body, and said hardened fluid serving as artificial hip joint surface.

Claims (23)

1. A system for resurfacing at least one carrying contacting surface of the joint, the system comprising:

a mould adapted to be introduced into a joint of a human patient for receiving material for resurfacing at least one carrying contacting surface of the joint, and

a material adapted to be injected into said mold, when implanted, and wherein said mould comprises a mould material adapted to chemically react with the injected material such that said mould melts or is resorbed by the human body after having received the injected material and thus served its purpose.

2. The system according to claim 1 , wherein said mould comprises a hyaluronan-based material.

3. The system according to claim 2 , wherein said material comprises hyaluronidase, and wherein the material of said mould is affected by the injection of the hyaluronidase such that the mould melts or is resorbed faster than without the injection of the hyaluronidase.

4. The system according to claim 1 , wherein said mould comprises a fibrin-based material.

5. The system according to claim 4 , wherein said material comprises plasmin, and wherein the material of said mould is affected by the injection of the plasmin such that the mould melts or is resorbed faster than without the injection of the plasmin.

6. The system according to claim 1 , wherein said mould comprises a collagen-based material.

7. The system according to claim 6 , wherein said material comprises collagenase, and wherein the material of said mould is affected by the injection of the collagenase such that the mould melts or is resorbed faster than without the injection of the collagenase.

8. The system according to claim 1 , wherein said mould comprises a chitosan-based material.

9. The system according to claim 8 , wherein said material comprises lysozyme, and wherein the material of said mould is affected by the injection of the lysozyme such that the mould melts or is resorbed faster than without the injection of the lysozyme.

10. The system according to claim 1 , wherein said material comprises at least one material selected from the group consisting of:

a. polytetrafluoroethylene,

b. perfluoroalkoxy

c. fluorinated ethylene propylene,

d. polyethylene, and

e. acrylic polymer mixed with alumina trihydrate.

11. The system according to claim 1 , wherein said mould is collapsible such that said mould can be introduced into the hip joint through a hole in any of: the pelvic bone, the femoral bone and the hip joint capsule.

12. The system according to claim 1 , wherein said mould is collapsible such that said mould can be introduced into the knee joint through a hole in any of: the femoral bone, the tibia bone and the knee joint capsule.

13. The system according to claim 1 , further comprising an injecting entrance in said mould adapted to receive injected material into said mould.

14. The system according to claim 1 , wherein said mould comprises an inner coating.

15. The system according to claim 14 , wherein said inner coating comprises a biocompatible phospholid polymer, the biocompatible phospholid polymer being 2-methacryloyloxyethyl phosphorylcholine (MPC).

16. The system according to claim 15 , wherein the inner coating comprising MPC is adapted to be grafted to the outer surface of the injected material.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE PREVIOUSLY RECORDED ON REEL 32252 FRAME 391. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 30, 2025
From: MILUX HOLDING S.A.
To: KIRK PROMOTION LTD.
Reel/Frame 074754/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2014
From: KIRK PROMOTION LTD.
To: FORSELL, PETER
Reel/Frame 032910/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2014
From: MILUX HOLDING S.A.
To: KIRK PROMOTION LTD.
Reel/Frame 032252/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2012
From: FORSELL, PETER
To: MILUX HOLDING SA
Reel/Frame 027508/0455 →